23 September 2024
Kromek Group
plc
("Kromek"
or the "Group")
Kromek selected for UK Government
Radiological Nuclear Detection Framework
Kromek (AIM: KMK), a leading developer
of radiation and bio-detection technology solutions for the
advanced imaging and CBRN detection segments, is pleased to
announce that it has been selected as a supplier under the UK
Government's Radiological Nuclear Detection
Framework (the "Framework") for the procurement of radiological
nuclear ("RN") detection equipment and supporting services for the
Home Office.
The Framework was established to
co-ordinate the RN detection procurement requirements and
capabilities of the Home Office, Counter Terrorism Police and other
public bodies to support Home Office strategic aims and to deliver
enhancements to the UK's end-to-end system for domestic nuclear
security. Kromek applied for three of the four Framework
categories, covering the supply of handheld, wearable and large
volume static radiation detectors, and was successfully approved
and awarded a Framework contract. Accordingly, Kromek is
pre-qualified to be selected for orders in these categories, which
over the four-year term of the Framework have a combined maximum
procurement value of £84 million. The Group will provide further
updates as and when there is progress in respect of any contracts
within these three Framework categories.
Arnab Basu,
CEO of Kromek, said: "We are delighted to have
become one of the few companies approved for the supply of
radiological nuclear detection equipment under this important Home
Office initiative. We have been providing our detectors to the UK
government for several years and it is great to see the continued
expansion of programmes that will enhance the UK's protection
against radiological threats. Alongside our recent selection under
the UK Government Resilience Framework for supplying emergency
services operators and our contract award from the Ministry of
Defence, we are experiencing excellent momentum in this area of our
business and we look forward to reporting on further
progress."
For
further information, please contact:
Kromek Group
plc
|
|
Arnab Basu, CEO
Paul Farquhar,
CFO
|
+44 (0)1740 626 060
|
|
|
Cavendish Capital Markets Limited (Nominated Adviser and
Broker)
|
|
Geoff Nash/Giles Balleny/Seamus
Fricker - Corporate Finance
Tim Redfern - ECM
|
+44 (0)20
7220 0500
|
Michael Johnson/Tamar Cranford-Smith - Sales
|
|
Gracechurch Group
(Financial PR)
|
|
Harry Chathli/Claire Norbury/Henry Gamble
|
+44 (0)20 4582 3500
|
Kromek Group
plc
Kromek Group plc is a leading developer of radiation
detection and bio-detection technology solutions for the advanced
imaging and CBRN detection segments. Headquartered in County
Durham, UK, Kromek has manufacturing operations in the UK and US,
delivering on the vision of enhancing the quality of life through
innovative detection technology
solutions.
The advanced imaging segment comprises the medical,
security and industrial markets. Kromek provides its OEM customers
with detector components, based on its core cadmium zinc telluride
(CZT) platform, to enable better detection of diseases such as
cancer and Alzheimer's, contamination in industrial manufacture and
explosives in aviation settings.
In CBRN detection, the Group provides nuclear
radiation detection solutions to the global homeland defense and
security market. Kromek's compact, handheld, high-performance
radiation detectors, based on advanced scintillation technology,
are primarily used to protect critical infrastructure and urban
environments from the threat of 'dirty
bombs'.
The Group is also developing bio-security solutions
in the CBRN detection segment. These consist of fully automated and
autonomous systems to detect a wide range of airborne
pathogens.
Kromek is listed on AIM, a market of the London Stock
Exchange, under the trading symbol
'KMK'.
Further information is available at
www.kromek.com.